Sugi Predict

Sugi Predict / Compounds / SCHEMBL7939686

SCHEMBL7939686

SCHEMBL7939686

O=C(c1cccs1)N1CCN(c2ccc([N+](=O)[O-])c(-n3nc(-c4ccccc4)c4ccccc4c3=O)c2)CC1

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.72
▸ HTT P42858 1/20 0.72
▸ HTR6 P50406 1/20 0.72
▸ LMNA P02545 3/20 0.59
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ NPSR1 Q6W5P4 7/20 0.55
▸ GAA P10253 1/20 0.55
▸ DCTPP1 Q9H773 1/20 0.53
▸ MAPK1 P28482 4/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2481272 0.84 MAPT (1.00) MAPTHTTHTR6LMNAMEN1
SCHEMBL4723117 0.83 MAPT (0.83) MAPTHTTHTR6LMNAMEN1
SCHEMBL4723139 0.82 MAPT (0.82) MAPTHTTHTR6LMNAMEN1
SCHEMBL4722514 0.81 MAPT (0.74) MAPTHTTHTR6LMNAMEN1
SCHEMBL4721650 0.81 MAPT (0.76) MAPTHTTHTR6LMNAMEN1
SCHEMBL4724178 0.79 MAPT (0.73) MAPTHTTHTR6LMNAMEN1
SCHEMBL2483606 0.78 ALDH1A1 (0.69) MAPTHTR6LMNAMEN1KMT2A
SCHEMBL4723607 0.78 MAPT (0.80) MAPTHTTHTR6LMNAMEN1
SCHEMBL1843766 0.78 NPSR1 (0.74) MAPTHTTHTR6LMNAMEN1
SCHEMBL2463380 0.77 DCTPP1 (0.67) MAPTLMNAMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11568956-B2 Methods for identifying inhibitors of amyloid protein aggregation TREVENTIS CORPORATION (US) 2023-01-31 — — US disclosed
US-20190050526-A1 METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION TREVENTIS CORPORATION (US) 2019-02-14 — — US disclosed
US-20160283652-A1 METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION TREVENTIS CORPORATION (US) 2016-09-29 — — US disclosed
US-20160283652-A1 METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION TREVENTIS CORPORATION (US) 2016-09-29 — — US disclosed
US-8420640-B2 Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine TREVENTIS CORPORATION (US) 2013-04-16 — — US disclosed
US-8420640-B2 Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine TREVENTIS CORPORATION (US) 2013-04-16 — — US disclosed
US-20110218200-A1 METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE TREVENTIS CORPORATION 2011-09-08 — — US disclosed
US-20110218200-A1 METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE TREVENTIS CORPORATION 2011-09-08 — — US disclosed
WO-2010025375-A1 COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE TREVENTIS CORPORATION (US) 2010-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218200-A1 METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE PSEN1, PSEN2, APP MAPT 10/4885HTT 8/4885HTR6 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.